Clinical Outcomes and Prognostic Factors in Soft Tissue Sarcoma Patients After Unplanned Excision

Figures & data

Table 1 Clinical Characteristics of the PE and the UE Patients

	PE Group	UE Group	P value
Median age (range, years)	58 (0.1–91)	61 (30–88)	0.183
Median tumor size (range, cm)	7.50 (1.5–35.2)	3.55 (0.5–18)	*< 0.01
Median F/U period (range, month)	89.5 (1–258)	95.5 (10–258)	0.405
Sex			*0.044
Men	52	17
Women	58	7
Depth			*< 0.01
Superficial	24	17
Deep	86	7
Surgical procedures			0.195
Wide resection	93	23
Amputation	17	1
Plastic reconstruction			*< 0.01
Yes	18	12
No	92	12
Adjuvant chemotherapy			0.164
Yes	11	5
No	99	19
Adjuvant radiotherapy			1
Yes	10	2
No	100	22
Margins of resected specimen			1
Positive	13	3
Negative	97	21
Local recurrence			0.775
Yes	20	5
No	90	19
Distant metastasis			*0.020
Yes	48	4
No	62	20

Note: Asterisk (*) indicates P value smaller than 0.05.

Abbreviations: F/U, follow-up; PE, planned excision; UE, unplanned excision.

Table 2 Histological Subtypes of the Primary Tumor in the PE and the UE Groups

Histological Subtypes	PE Group (%)	UE Group (%)
UPS/MFH	20 (18.2)	5 (20.8)
Myxofibrosarcoma	15 (13.6)	6 (25.0)
Leiomyosarcoma	14 (12.7)	4 (16.7)
Myxoid liposarcoma	13 (11.8)	4 (16.7)
Synovial sarcoma	8 (7.3)	2 (8.3)
Dedifferentiated liposarcoma	8 (7.3)	–
MPNST	7 (6.4)	2 (8.3)
Pleomorphic liposarcoma	3 (2.7)	–
Clear cell sarcoma	3 (2.7)	–
Rhabdomyosarcoma	3 (2.7)	–
EMC	3 (2.7)	–
Others	13 (11.8)	1 (4.2)
Total	110 (100)	24 (100)

Abbreviations: PE, planned excision; UE, unplanned excision; UPS/MFH, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma; MPNST, malignant peripheral nerve sheath tumor; EMC, extraskeletal myxoid chondrosarcoma.

Table 3 Primary Tumor Site in the PE and the UE Groups

Sites	PE Group (%)	UE Group (%)
Thigh	38 (34.5)	8 (33.3)
Lower leg	15 (13.6)	6 (25.0)
Trunk	14 (12.7)	5 (20.8)
Buttock	9 (8.2)	2 (8.3)
Forearm	8 (7.3)	3 (12.5)
Upper arm	5 (4.5)	–
Knee	5 (4.5)	–
Foot	5 (4.5)	–
Shoulder	4 (3.6)	–
Ankle	3 (2.7)	–
Hand	2 (1.8)	–
Others	5 (4.5)	–
Total	110 (100)	24 (100)

Abbreviations: PE, planned excision; UE, unplanned excision.

Figure 1 Survival in patients with soft tissue sarcoma undergoing planned (PE) and unplanned (UE) excision. (A) Overall survival (P = 0.385). (B) Local recurrence-free survival (P = 0.953). (C) Metastasis-free survival (P = 0.021). (D) Disease-free survival (P = 0.155).

Table 4 Univariate Analyses for DFS in the UE Group

	n	5-Year Survival Rate (%)	Median Survival (Month)	P value
Sex				0.77
Men	17	64.7	77.0
Women	7	71.4	69.0
Depth				0.595
Superficial	17	70.6	69.0
Deep	7	57.1	97.0
Residual tumor cells				0.875
Yes	15	66.7	94.0
No	9	66.7	66.0
Surgical procedures				*0.043
Wide resection	23	69.6	77.0
Amputation	1	0	9.0
Plastic reconstruction				0.982
Yes	12	66.7	71.5
No	12	66.7	76.5
Adjuvant chemotherapy				0.278
Yes	5	40.0	45.0
No	19	73.7	77.0
Adjuvant radiotherapy				0.612
Yes	2	50.0	88.5
No	22	68.2	73.0
Age (years)				*0.048
≥ 61	14	50.0	52.5
< 61	10	90.0	118.0
Tumor size (cm)				*0.039
≥ 2.9	17	52.9	60.0
< 2.9	7	100	124.0
Margins of additionally resected specimen				0.478
Positive	3	66.7	98.0
Negative	21	66.7	69.0

Note: Asterisk (*) indicates P value smaller than 0.05.

Abbreviations: DFS, disease-free survival; UE, unplanned excision.

Figure 2 Receiver operating characteristic curve analyses in patients with soft tissue sarcoma undergoing unplanned excision. (A) Relationship between age at primary tumor diagnosis and disease-free survival (DFS). (B) Relationship between primary tumor size and DFS.

Figure 3 Kaplan–Meier survival curves for disease-free survival in patients with soft tissue sarcoma undergoing unplanned excision. (A) By age at primary tumor diagnosis (P = 0.048). (B) By primary tumor size (P = 0.039).